Skip to content

Neurocognitive Outcomes in Mild Hyperphenylalaninemia (MHP)MHP Study

Neuropsychological and Quality of Life Outcomes in Untreated Adults With Mild Hyperphenylalaninemia (MHP)/Phenylketonuria (PKU) With Phenylalanine Levels Between 360 and 600 µmol/L Caused by Phenylalanine Hydroxylase (PAH) Deficiency.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01924026
Enrollment
10
Registered
2013-08-16
Start date
2013-09-30
Completion date
2016-02-29
Last updated
2016-02-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mild Hyperphenylalaninemia, Phenylketonuria

Keywords

Phenylketonuria, Mild Hyperphenylalaninemia, PKU, MHP

Brief summary

Phenylketonuria (PKU) is a genetic disorder known to cause severe reduction in intelligence and deficits in cognitive function; it is associated with an elevated level of Phenylalanine (Phe) in blood. Newborn screening and early treatment with restricted protein diet supplemented by a formula of amino-acids will preserve intelligence. In those with the severe form treated from birth, some deficits that affect higher functions of the brain are seen. Given this, there is disagreement about how milder forms of this disease should be managed and what level of Phe is safe to be left untreated. We seek to assess whether higher Phe levels, between 360 and 600µmol/L, are safe with respect to preservation of intelligence and higher cognitive functions.

Detailed description

The following personal/medical information will be collected and reviewed: * Evaluation of current and past medical history, including psychological treatment such as medication and counseling/therapy. * Mutational analysis for each MHP subject * Detailed history of educational, employment, relationship, and socioeconomic status/achievements as a measure of successful transition to adulthood * Diet history, including past treatment with medical food or Sapropterin (Kuvan) for pre-conceptual and pregnancy Phe management * All available untreated Phe levels, including newborn screening results (where possible) will be collated to calculate lifetime mean Phe level. Age at collections will be recorded separately for each MHP subjects to ensure inclusion of Phe levels beyond infancy The following clinical investigations will be administered: * Measurement of Phe and Tyrosine after an overnight fast, via blood spot using tandem mass spectrometry analysis. Blood spot collection will be done at the same time of day for all subjects. * Physical exam, height and weight measurements * Food Frequency Questionnaire assessment to estimate typical daily intake of natural protein. * Self-Report Questionnaires: * Behavior Rating Inventory of Executive Function (BRIEF)-A * Beck Anxiety Inventory * Beck Depression Inventory * Quality of Life questionnaire * Neuropsychological Tests assessed by a trained psychologist An informant BRIEF-A report will be completed for each subject. To ensure consistency in rating, the same informant will be used where possible for the MHP subject and their sibling control (i.e. parents). These questionnaires will be mailed to the informants and returned to the study site via FedEx.

Interventions

None listed

Sponsors

BioMarin Pharmaceutical
CollaboratorINDUSTRY
The Hospital for Sick Children
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male or Female, ≥ 18 years * Confirmed to have MHP with at least two Phe levels during lifetime of above 360µmol/L and below 600µmol/L, including newborn screening levels (available since 1968 by either bacterial inhibition, enzymatic or tandem mass spectrometry methodology) and via mutation analysis. Those with occasional levels above 600µmol/L will not be excluded provided the majority of available levels fall within the 360-600µmol/L range. * On an unrestricted diet and not taking medical food. Women who were on dietary or Kuvan® treatment for past pre-conception or pregnancy management will not be excluded * Willing and able to give consent and comply with study procedures.

Exclusion criteria

* Subjects on dietary or Kuvan® treatment within the last 12 weeks will be excluded. * Co-morbidities that may interfere with study participation and/or put the subject at a higher risk of adverse effects. Subjects who do not have an unaffected sibling may still participate.

Design outcomes

Primary

MeasureTime frameDescription
Executive functionDay 1As measured by subtests in Weschler-IV test, and supplemented with assessments from BRIEF-A and CANTAB(computerised cognitive tests by Cambridge Cognition).

Secondary

MeasureTime frameDescription
Quality of LifeDay 1
Presence of anxiety and depressionDay 1As measured by Beck Anxiety and Depression Inventories

Other

MeasureTime frameDescription
IQDay 1As measured by Wechsler-IV

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026